Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Corcept TherapeuticsFRA:HTD -1.61%85 Net Cash per Share is €1.01 as of Jun. 2026, which is 100% below its 10-year median of 10.01. GuruFocus rates FRA:HTD with a GF Score™ of 85/100 and a GF Value™ of €59.36 (Significantly Overvalued). The stock has 9 warning signs investors should review. Among 796 Biotechnology companies, Corcept Therapeutics ranks worse than 96.61% on this metric.
Corcept Therapeutics (FRA:HTD) Net Cash per Share Explanation
Ben Graham invested in situations where the company's stock price was lower than its net-cash. He assigned some value to the company's other current asset. The value is called Net Current Asset Value (NCAV). One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham's strategy produced similar results.
You can find companies that are traded below their Net Current Asset Value (NCAV) with our Net-Net screener.
Corcept Therapeutics Net Cash per Share Related Terms
Corcept Therapeutics Net Cash per Share Historical Data
* Premium members only.
The historical data trend for Corcept Therapeutics's Net Cash per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:HTD vs APGE, KRYS, NUVL: Net Cash per Share Comparison
For the Biotechnology subindustry, Corcept Therapeutics's Price-to-Net-Cash, along with its competitors' market caps and Price-to-Net-Cash data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Corcept Therapeutics Price-to-Net-Cash vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Corcept Therapeutics's Price-to-Net-Cash distribution charts can be found below:
* The bar in red indicates where Corcept Therapeutics's Price-to-Net-Cash falls into.
Corcept Therapeutics Net Cash per Share Calculation
In the calculation of a company's Net Cash per Share, assets other than cash and short term investments are considered to be worth nothing. But the company has to pay its debt and other liabilities in full. This is an extremely conservative way of valuation. Most companies have negative Net Cash per Share. But sometimes a company's price may be lower than its net-cash.
Corcept Therapeutics's Net Cash per Share for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Corcept Therapeutics (FRA:HTD) has a Net Cash per Share of €1.01 as of Jun. 2026. Net cash per share equals the per-share value of cash and equivalents less total liabilities and minority interest. View historical data on Corcept Therapeutics and its competitors. This is 90% below median its historical median of 10.01. Over the past decade, Corcept Therapeutics' Net Cash per Share has ranged from 5.02 to 96.72. According to the industry distribution chart, Corcept Therapeutics ranks #769 out of 796 companies in the Biotechnology industry, placing it in the top 96.6%.
Is Corcept Therapeutics' Net Cash per Share too high?
Corcept Therapeutics' current Net Cash per Share of €1.01 is 90% below median its 10-year median of 10.01. Over the past 10 years, this metric has ranged from a low of 5.02 to a high of 96.72. Based on the distribution chart, Corcept Therapeutics ranks #769 out of 796 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Corcept Therapeutics has a GF Score™ of 85/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Corcept Therapeutics' Net Cash per Share compare to APGE and KRYS?
According to the Biotechnology industry distribution chart, Corcept Therapeutics ranks #769 out of 796 companies for Net Cash per Share. This places Corcept Therapeutics in the lower half of its industry. The industry median Net Cash per Share is 5.20. Historically, Corcept Therapeutics' own Net Cash per Share has ranged from 5.02 to 96.72 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Cash per Share for a Biotechnology company?
The median Net Cash per Share among Biotechnology companies is 5.20, based on 796 companies in the industry. Companies in the top quartile (top 25%) have a Net Cash per Share significantly above this median, while those in the bottom quartile fall well below. However, Net Cash per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Cash per Share mean?
A high Net Cash per Share can signal that a stock is expensive relative to its fundamentals. Net cash per share equals the per-share value of cash and equivalents less total liabilities and minority interest. View historical data on Corcept Therapeutics and its competitors. For the Biotechnology industry, the median Net Cash per Share is 5.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Corcept Therapeutics's current Net Cash per Share is €1.01, which is 90% below median its own 10-year median of 10.01. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Corcept Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Corcept Therapeutics (FRA:HTD) is currently considered Significantly Overvalued. The stock's GF Value™ is €59.36, compared to a current price of €96.72 — trading 62.9% above its estimated fair value. The current Net Cash per Share is €1.01, which is 90% below median its 10-year median of 10.01. Corcept Therapeutics' overall GF Score™ is 85/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Cash per Share calculated?
Net Cash per Share is calculated from a company's financial statements. For Corcept Therapeutics (FRA:HTD), the current Net Cash per Share is €1.01 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Corcept Therapeutics (FRA:HTD) Overvalued in 2026?
Based on GuruFocus' analysis, Corcept Therapeutics stock appears to be overvalued.
The current stock price of €96.72 is trading 62.9% above its estimated GF Value™ of €59.36.
GuruFocus considers Corcept Therapeutics to be Significantly Overvalued.
Key valuation signals for FRA:HTD:
Net Cash per Share: €1.01 (90% below median its 10-year median of 10.01)
GF Value™: €59.36 vs. price of €96.72 (62.9% above fair value)
No single metric tells the full story. See the FRA:HTD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic, and neuropsychiatric disorders by modulating the effect of the cortisol hormone. The company markets Korlym (mifepristone) tablets and its authorized generic version, which is an oral medication for the treatment of hypercortisolism (also known as Cushing's syndrome). Additionally, its pipeline contains several key compounds, such as Relacorilant, Dazucorilant, Miricorilant, etc., that are being evaluated in clinical trials as potential treatments for a variety of serious disorders like hypercortisolism, solid tumors (including ovarian, endometrial, cervical, pancreatic, and prostate cancers), ALS, and MASH.
85GF Score
Get the complete analysis for FRA:HTD
Net Cash per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:HTD has been successfully added to your 
